甲磺酸阿帕替尼联合卡瑞利珠单抗治疗原发性肝癌伴肺转移一例 - betway必威登陆网址

国际肿瘤学杂志››2020,Vol. 47››Issue (8): 510-512.doi:10.3760/cma.j.cn371439-20191111-00068

• 病例报道 •上一篇

甲磺酸阿帕替尼联合卡瑞利珠单抗治疗原发性肝癌伴肺转移一例

张伟, 殷海涛(), 周冲, 李向阳, 郭林

江苏省徐州市中心医院放疗科 221009

收稿日期:2019-11-11修回日期:2019-12-08出版日期:2020-08-08发布日期:2020-10-22
通讯作者:殷海涛 E-mail:baxia1108@126.com

Received:2019-11-11Revised:2019-12-08Online:2020-08-08Published:2020-10-22

摘要/Abstract

摘要：

大多数肝癌患者发病时已为中晚期,且缺乏有效治疗手段,预后极差。本研究报道采用甲磺酸阿帕替尼联合卡瑞利珠单抗二线以上治疗1例原发性肝癌伴肺转移病例,取得了显著疗效,为晚期原发性肝癌的治疗提供了新的方法。

张伟, 殷海涛, 周冲, 李向阳, 郭林. 甲磺酸阿帕替尼联合卡瑞利珠单抗治疗原发性肝癌伴肺转移一例[J]. 国际肿瘤学杂志, 2020, 47(8): 510-512.

图/表4

参考文献8

[1]	Jain RK. Antiangiogenesis strategies revisted: from starving tumors to alleviating hypoxia[J]. Cancer Cell, 2014,26(5):605-622. DOI: 10.1016/j.ccell.2014.10.006. doi:10.1016/j.ccell.2014.10.006
[2]	Nie J, Wang C, Liu Y, et al. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma[J]. J Clin Oncol, 2019,37(17):1479-1489. DOI: 10.1200/JCO.18.02151. doi:10.1200/JCO.18.02151pmid:31039052
[3]	Song Y, Wu J, Chen X, et al. A single-arm multicenter, phase Ⅱ study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma[J]. Clin Cancer Res, 2019,25(24):7363-7369. DOI: 10.1158/1078-0432.CCR-19-1680. doi:10.1158/1078-0432.CCR-19-1680pmid:31420358
[4]	Xu J, Zhang Y, Jia R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophago-gastric iunction cancer: an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019,25(2):515-523. DOI: 10.1158/1078-0432.CCR-18-2484. doi:10.1158/1078-0432.CCR-18-2484pmid:30348638
[5]	Huang J, Mo H, Zhang W, et al. Promising efficacy of SHR-1210, a noval anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China[J]. Cancer, 2019,125(5):742-749. DOI: 10.1002/cncr.31855. pmid:30508306
[6]	Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma[J]. Clin Cancer Res, 2018,24(6):1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439. pmid:29358502
[7]	Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018,19(10):1338-1350. DOI: 10.1016/s1470-2045(18)30495-9. doi:10.1016/S1470-2045(18)30495-9pmid:30213452
[8]	Hause RJ, Pritchard CC, Shendure J, et al. Classification and characterization of microsatellite instability across 18 cancer types[J]. Nat Med, 2016,22(11):1342-1350. DOI: 10.1038/nm.4191. pmid:27694933

相关文章15

编辑推荐

Metrics

本文评价